Two studies give hope for some Mesothelioma lung cancer patients

A new drug for cancer called “Iereesa” impressive results in the treatment of lung cancer, which is considered the most deadly types of cancer in most countries of the world.

However, the limits of the “Iereesa” that the rate of only 15% of the patients to enable them benefit from the research after the lack of response from the majority of patients to the drug.

The teams from Harvard Medical School in Boston, and other hospitals, there is a change in the gene controlling the protein growth factor called the future of skin cancer in patients with non-small cell lung, so the cells are not able to control it might be fatal in the end.

The non-small lung cancer cell responsible for the deaths of 85% of lung cancers, and caused the deaths of more than 157 people in the United States last year.

The researchers said that the Americans are genetically rapid examination may help to identify any of the injured lung cancer to enable them to benefit from Iereesa.

And Dr. William Sellers of Dana-Farber Cancer Institute at Harvard University who participated in the study, said that “Iereesa” failed to obtain a license from the U.S. Food and Drug Administration because the positive results did not appear only on a small percentage of patients.

He also expressed fear that pharmaceutical companies use the study to pressure in order to obtain a license to and delivery of cancer drugs to patients in need.
Source: Reuters

This Informations Collected And Translated From Arabic Language By Mesothelioma Guide